NRSNW

NeuroSense Therapeutics Ltd.

Price Chart

Latest Quote

$0.09

+0.00 (+0.00%)

Current Price

Previous Close	$0.09
Open	$0.30
Day High	$0.09
Day Low	$0.08
Volume	3,760

Fetched: 2026-06-23T22:48:13

Stock Information

Total Debt	$170K
Cash Equivalents	$166K
Net Income	$-11.12M
EPS (TTM)	$-0.94
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Income	$-11.12M
Book/sh	$-0.05
Employees	17

Financial Ratios

Quick Ratio	0.08
Current Ratio	0.31

Returns & Margins

ROA	-247.30%
ROE	-2174.98%

Ownership

Insider & Institutional transactions data not available

Valuation Ratios

P/B

-1.89

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$0.21
SMA50	$0.21
RSI	nan

Shares Float	21.40M
Volatility	1.54

Performance History

Week	+0.00%
Month	+0.00%
Quarter	+0.00%
YTD	+0.00%
10 Years	+0.00%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$0.21	0
2026-06-17	$0.21	0
2026-06-16	$0.21	0
2026-06-15	$0.21	0
2026-06-12	$0.21	0
2026-06-11	$0.21	0
2026-06-10	$0.21	0
2026-06-09	$0.21	0
2026-06-08	$0.21	0
2026-06-05	$0.21	0
2026-06-04	$0.21	0
2026-06-03	$0.21	0
2026-06-02	$0.21	0
2026-06-01	$0.21	0
2026-05-29	$0.21	0
2026-05-28	$0.21	0
2026-05-27	$0.21	0
2026-05-26	$0.21	0

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

📰 Latest News

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires • 2025-09-10T19:52:18Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$11,085,000	$9,902,000	$12,049,000	$10,554,000
Other Income Expense	$-47,000	$1,000	$2,212,000	$-22,000
Net Non Operating Interest Income Expense	$7,000	$-309,000	$-270,000	$84,000
Total Other Finance Cost	$6,000	$311,000	$448,000	$7,000
Operating Expense	$11,085,000	$9,902,000	$12,049,000	$10,554,000
General And Administrative Expense	$4,858,000	$4,204,000	$4,775,000	$4,967,000
Interest Expense	-	-	$11,000	$15,000
Interest Expense Non Operating	-	-	$11,000	$15,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Net Interest Income	$7,000	$-309,000	$-270,000	$84,000
Interest Income	$13,000	$2,000	$178,000	$91,000
Normalized Income	$-11,078,000	$-10,211,000	$-12,319,000	$-10,470,000
Net Income From Continuing And Discontinued Operation	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Total Operating Income As Reported	$-11,085,000	$-9,902,000	$-12,049,000	$-10,554,000
Net Income Common Stockholders	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Net Income	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Net Income Including Noncontrolling Interests	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Net Income Continuous Operations	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Pretax Income	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Interest Income Non Operating	$13,000	$2,000	$178,000	$91,000
Operating Income	$-11,085,000	$-9,902,000	$-12,049,000	$-10,554,000
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-11,022,000	$-9,881,000	$-14,240,000	$-10,520,000
Total Unusual Items	$-47,000	$1,000	$2,212,000	$-22,000
Total Unusual Items Excluding Goodwill	$-47,000	$1,000	$2,212,000	$-22,000
Reconciled Depreciation	$16,000	$22,000	$21,000	$12,000
EBITDA (Bullshit earnings)	$-11,069,000	$-9,880,000	$-12,028,000	$-10,542,000
EBIT	$-11,085,000	$-9,902,000	$-12,049,000	$-10,554,000
Diluted NI Availto Com Stockholders	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Gain On Sale Of Security	$-47,000	$1,000	$2,212,000	$-22,000
Research And Development	$6,227,000	$5,698,000	$7,274,000	$5,587,000
Selling General And Administration	$4,858,000	$4,204,000	$4,775,000	$4,967,000
Other Gand A	$2,760,000	$2,666,000	$2,291,000	$1,621,000
Insurance And Claims	$289,000	$309,000	$511,000	$1,174,000
Salaries And Wages	$1,809,000	$1,229,000	$1,973,000	$2,172,000

Fetched: 2026-06-19

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-1,560,000	$2,583,000	$-1,759,000	$5,619,000
Total Assets	$1,028,000	$4,575,000	$3,185,000	$7,710,000
Total Non Current Assets	$250,000	$173,000	$269,000	$329,000
Other Non Current Assets	$22,000	$23,000	$22,000	$23,000
Current Assets	$778,000	$4,402,000	$2,916,000	$7,381,000
Restricted Cash	$47,000	$35,000	$40,000	$36,000
Prepaid Assets	$532,000	$825,000	$70,000	$124,000
Receivables	$33,000	$164,000	$166,000	$131,000
Other Receivables	$33,000	$164,000	$166,000	$131,000
Cash Cash Equivalents And Short Term Investments	$166,000	$3,378,000	$2,640,000	$7,090,000
Cash And Cash Equivalents	$166,000	$3,378,000	$2,640,000	$3,543,000
Cash Financial	-	-	-	-
Debt
Total Debt	$170,000	$73,000	$142,000	$211,000
Long Term Debt And Capital Lease Obligation	$72,000	$0	$73,000	$147,000
Current Debt And Capital Lease Obligation	$98,000	$73,000	$69,000	$64,000
Liabilities
Total Liabilities Net Minority Interest	$2,588,000	$1,992,000	$4,944,000	$2,091,000
Total Non Current Liabilities Net Minority Interest	$72,000	$0	$1,485,000	$365,000
Current Liabilities	$2,516,000	$1,992,000	$3,459,000	$1,726,000
Payables And Accrued Expenses	$2,418,000	$1,919,000	$3,390,000	$1,292,000
Payables	$799,000	$1,160,000	$1,459,000	$498,000
Accounts Payable	$799,000	$1,160,000	$1,459,000	$498,000
Derivative Product Liabilities	-	$0	$1,412,000	$218,000
Equity
Common Stock Equity	$-1,560,000	$2,583,000	$-1,759,000	$5,619,000
Total Equity Gross Minority Interest	$-1,560,000	$2,583,000	$-1,759,000	$5,619,000
Stockholders Equity	$-1,560,000	$2,583,000	$-1,759,000	$5,619,000
Retained Earnings	$-47,785,000	$-36,660,000	$-26,121,000	$-20,786,000
Other
Ordinary Shares Number	$32,557,174	$23,228,941	$15,379,042	$11,781,963
Share Issued	$32,557,174	$23,228,941	$15,379,042	$11,781,963
Tangible Book Value	$-1,560,000	$2,583,000	$-1,759,000	$5,619,000
Invested Capital	$-1,560,000	$2,583,000	$-1,759,000	$5,619,000
Working Capital	$-1,738,000	$2,410,000	$-543,000	$5,655,000
Capital Lease Obligations	$170,000	$73,000	$142,000	$211,000
Total Capitalization	$-1,560,000	$2,583,000	$-1,759,000	$5,619,000
Additional Paid In Capital	$46,225,000	$39,243,000	$24,362,000	$26,405,000
Capital Stock	$0	$0	$0	$0
Common Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$72,000	$0	$73,000	$147,000
Current Capital Lease Obligation	$98,000	$73,000	$69,000	$64,000
Current Accrued Expenses	$1,619,000	$759,000	$1,931,000	$794,000
Net PPE	$228,000	$150,000	$247,000	$306,000
Accumulated Depreciation	$-76,000	$-60,000	$-38,000	$-17,000
Gross PPE	$304,000	$210,000	$285,000	$323,000
Leases	$3,000	$3,000	$3,000	$3,000
Machinery Furniture Equipment	$131,000	$123,000	$120,000	$91,000
Buildings And Improvements	$170,000	$84,000	$162,000	$229,000
Properties	$0	$0	$0	$0
Pensionand Other Post Retirement Benefit Plans Current	-	-	$209,000	$370,000
Other Short Term Investments	-	-	$0	$3,547,000
Other Properties	-	-	-	$229,000

Fetched: 2026-06-19

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-7,679,000	$-10,138,000	$-8,383,000	$-7,686,000
Operating Activities
Operating Cash Flow	$-7,671,000	$-10,135,000	$-8,354,000	$-7,616,000
Cash Flow From Continuing Operating Activities	$-7,671,000	$-10,135,000	$-8,354,000	$-7,616,000
Operating Gains Losses	-	$-46,000	$-2,191,000	$-1,166,000
Investing Activities
Capital Expenditure	$-8,000	$-3,000	$-29,000	$-70,000
Investing Cash Flow	$-8,000	$1,000	$3,468,000	$-3,590,000
Cash Flow From Continuing Investing Activities	$-8,000	$1,000	$3,468,000	$-3,590,000
Net Other Investing Changes	-	$4,000	$-3,000	$-20,000
Financing Activities
Issuance Of Capital Stock	$4,531,000	$11,304,000	$4,334,000	$0
Financing Cash Flow	$4,432,000	$10,913,000	$3,975,000	$3,774,000
Cash Flow From Continuing Financing Activities	$4,432,000	$10,913,000	$3,975,000	$3,774,000
Net Other Financing Charges	$-121,000	$-391,000	$-364,000	-
Net Common Stock Issuance	$4,531,000	$11,304,000	$4,334,000	$0
Common Stock Issuance	$4,531,000	$11,304,000	$4,334,000	$0
Other
End Cash Position	$166,000	$3,378,000	$2,640,000	$3,543,000
Beginning Cash Position	$3,378,000	$2,640,000	$3,543,000	$11,063,000
Effect Of Exchange Rate Changes	$35,000	$-41,000	$8,000	$-88,000
Changes In Cash	$-3,247,000	$779,000	$-911,000	$-7,432,000
Proceeds From Stock Option Exercised	$22,000	$0	$5,000	$3,774,000
Net Investment Purchase And Sale	$0	$0	$3,500,000	$-3,500,000
Net PPE Purchase And Sale	$-8,000	$-3,000	$-29,000	$-70,000
Purchase Of PPE	$-8,000	$-3,000	$-29,000	$-70,000
Change In Working Capital	$1,344,000	$-781,000	$1,913,000	$1,095,000
Change In Other Current Liabilities	$-73,000	$-69,000	$-69,000	$-95,000
Change In Other Current Assets	$508,000	$-675,000	$93,000	$125,000
Change In Payables And Accrued Expense	$909,000	$-37,000	$1,889,000	$1,065,000
Change In Payable	$909,000	$-37,000	$1,889,000	$1,065,000
Change In Account Payable	$-361,000	$-299,000	$961,000	$459,000
Other Non Cash Items	$-46,000	$323,000	$473,000	$41,000
Stock Based Compensation	$2,140,000	$557,000	$1,537,000	$1,728,000
Depreciation Amortization Depletion	$16,000	$22,000	$21,000	$12,000
Depreciation And Amortization	$16,000	$22,000	$21,000	$12,000
Depreciation	$16,000	$22,000	$21,000	$12,000
Net Income From Continuing Operations	$-11,125,000	$-10,210,000	$-10,107,000	$-10,492,000
Gain Loss On Investment Securities	-	$-46,000	$-2,191,000	$-1,166,000
Repayment Of Debt	-	-	$-80,000	$-79,000
Net Issuance Payments Of Debt	-	-	$-80,000	$-79,000
Net Long Term Debt Issuance	-	-	$-80,000	$-79,000
Long Term Debt Payments	-	-	$-80,000	$-79,000
Interest Received Cfi	-	-	$178,000	$49,000
Change In Receivables	-	-	$19,000	$55,000
Gain Loss On Sale Of PPE	-	-	$0	$0
Purchase Of Investment	-	-	-	$-3,500,000

Fetched: 2026-06-19